HYPMY - Hypermarcas S.A.


4.35
-0.310   -7.126%

Share volume: 1,698
Last Updated: 03-03-2026

PREVIOUS CLOSE
CHG
CHG%

$4.66
-0.31
-0.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Performance
5 Days
-6.65%
1 Month
-1.36%
3 Months
-7.25%
6 Months
3.20%
1 Year
27.04%
2 Year
38.10%
Key data
Stock price
$4.35
P/E Ratio 
N/A
DAY RANGE
$4.14 - $4.35
EPS 
N/A
52 WEEK RANGE
$3.17 - $5.50
52 WEEK CHANGE
$26.09
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-24-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$16,274
AVERAGE 30 VOLUME 
$17,442
Company detail
CEO:
Region: US
Website: hyperapharma.com.br
Employees: 0
IPO year: 2010
Issue type:
Market: OTCM
Industry:
Sector:

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers branded prescription products under the Mantecorp Farmasa, Episol, Predsim, Alivium, Lisador, Rinosoro, Celestamine, Maxsulid, Diprospan, Mioflex-A, and Addera D3 brands; dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. The company also provides nutrition, sweeteners, and vitamin supplement products under the Tamarine, Vitasay 50+, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Torsilax, Neosoro, Doralgina, Flavonid, and Histamin brands. It sells its products through distributors and wholesalers. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

Recent news